Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 20, 2026, announces a definitive agreement to acquire RAPT Therapeutics, a clinical-stage biopharmaceutical company. The transaction focuses on acquiring ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food allergens. The deal is expected to close in the first quarter of 2026.
Key Financial Metrics
- Aggregate Equity Value: Estimated at $2.2 billion.
- Offer Price: $58.00 per share in cash.
- Upfront Investment: Estimated at $1.9 billion (net of cash acquired).
- Additional Obligations: GSK assumes responsibility for success-based milestone and royalty payments owed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co., Ltd.
- Accounting Treatment: The transaction will be accounted for as a business combination.
Material Changes and Strategic Rationale
The acquisition adds ozureprubart to GSK's Respiratory, Immunology & Inflammation pipeline. The asset targets a significant unmet need in food allergies, affecting over 17 million people in the US. Ozureprubart offers a potential dosing frequency of every 12 weeks, compared to the current standard of care requiring injections every 2 to 4 weeks. This improvement aims to enhance patient compliance and outcomes, particularly for the pediatric population which comprises 65% of severe food allergy patients. The acquisition grants GSK global rights to the program, excluding mainland China, Macau, Taiwan, and Hong Kong.
Outlook, Risks, and Contingencies
Timeline and Milestones: Data from the Phase IIb trial (prestIgE) is expected in 2027, with Phase III trials planned for at-risk adult and pediatric populations. The transaction is subject to customary closing conditions, including the tender of a majority of RAPT shares and the expiration of the Hart-Scott-Rodino Act waiting period.
Risks and Uncertainties: The filing includes extensive forward-looking statements cautioning that actual results may differ due to risks such as the failure to satisfy closing conditions, inability to obtain regulatory approvals, disruption of RAPT's operations, and the failure to realize anticipated benefits. The transaction is not guaranteed to close.
Investor Verification Checklist
- Verify the final closing date and confirmation of the tender offer results.
- Review the upcoming Schedule TO Tender Offer Statement and Schedule 14D-9 for detailed terms.
- Monitor the status of regulatory approvals, specifically under the Hart-Scott-Rodino Act.
- Assess the impact of the $1.9 billion upfront investment on GSK's liquidity and capital allocation strategy.
- Track the 2027 data readout for the prestIgE Phase IIb trial to validate the clinical profile of ozureprubart.